Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Molecular Partners Ag ADR
(NQ:
MOLN
)
5.680
-0.800 (-12.35%)
Streaming Delayed Price
Updated: 3:44 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Molecular Partners Ag ADR
< Previous
1
2
3
4
5
6
7
Next >
Molecular Partners Announces Dismissal of Class Action Lawsuit
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024
From
Molecular Partners
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 03, 2024
Via
Benzinga
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
December 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
December 10, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
November 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
November 03, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
November 01, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
October 26, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
September 13, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
August 24, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
June 27, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 19, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
May 16, 2023
From
Molecular Partners
Via
GlobeNewswire
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
May 11, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
April 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
April 04, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2023
March 13, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
March 09, 2023
From
Molecular Partners
Via
GlobeNewswire
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
March 07, 2023
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
March 02, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
February 28, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
February 10, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
January 16, 2023
From
Molecular Partners
Via
GlobeNewswire
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
January 08, 2023
From
Molecular Partners
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.